While nebulised hypertonic saline therapy in CF is reported to improve both SCN− and GSH airway surface liquid levels, a finding which was reproduced in a CFTR knockout animal model [23,83], there are no current clinical trials evaluating nebulised SCN− to date. This evidence concerns the gene CFTR and cystic fibrosis.